Insulet initiated a voluntary medical device correction affecting Omnipod insulin pump pods after identifying a manufacturing issue that could lead to insulin leakage and under-delivery of doses in some patients. The company’s action is positioned as a mitigation step while it addresses the underlying manufacturing concern. The correction matters for clinicians and diabetes program managers because it directly impacts dosing reliability in a device category that supports continuous therapy. Patient safety will depend on the scope of affected lots and Insulet’s remediation steps, including notifications and replacements. In a competitive market for automated insulin delivery, the event also increases attention on manufacturing controls and field performance monitoring.